Latest Articles
Neurocrine CEO and CFO to Share Strategic Updates at BofA and RBCCM Healthcare Conferences This May - Stock Titan
Neurocrine CEO and CFO to Share Strategic Updates at BofA and RBCCM Healthcare Conferences This May Stock Titan
Published: May 6, 2025, 8:01 p.m.
Western Sierra Medical Clinic to Host Free Event, Breaking the Cycle: Period Pain, Endometriosis Awareness and Women’s Health - YubaNet
Western Sierra Medical Clinic to Host Free Event, Breaking the Cycle: Period Pain, Endometriosis Awareness and Women’s Health YubaNet
Published: May 6, 2025, 3:02 p.m.
Join us at the Health Research Showcase 2025 - Oxford Health NHS Foundation Trust
Join us at the Health Research Showcase 2025 Oxford Health NHS Foundation Trust
Published: May 6, 2025, 12:20 p.m.
Up and coming: A new chapter for women’s health – IMMUNE MATTERS - La Jolla Institute
Up and coming: A new chapter for women’s health – IMMUNE MATTERS La Jolla Institute
Published: May 5, 2025, 7:47 p.m.
New endometriosis pill on the NHS could benefit more than 1,000 women a year - Health Tech World
New endometriosis pill on the NHS could benefit more than 1,000 women a year Health Tech World
Published: May 5, 2025, 11:03 a.m.
Olivia Orchowski on building Kyri: Wearable health tech for women - CommBank
Olivia Orchowski on building Kyri: Wearable health tech for women CommBank
Published: May 2, 2025, 3:35 p.m.
The Women’s Health Initiative has shaped women’s health for over 30 years, but its future is uncertain - inkl
The Women’s Health Initiative has shaped women’s health for over 30 years, but its future is uncertain inkl
Published: May 2, 2025, 12:44 p.m.
New at-home endometriosis treatment - National Health Executive
New at-home endometriosis treatment National Health Executive
Published: May 2, 2025, 9:44 a.m.
‘It’s Not Just a Period’: Lunaire raises awareness for women’s health at Warwick - The Boar
‘It’s Not Just a Period’: Lunaire raises awareness for women’s health at Warwick The Boar
Published: May 2, 2025, 9:01 a.m.
Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial.
To evaluate the safety and pharmacokinetics/pharmacodynamics of AMY109, an anti-interleukin-8 recycling antibody in a first-in-human phase 1 trial in healthy volunteers (HVs) and patients with endometriosis.
Published: May 2, 2025, midnight
Link copied to clipboard!